Mirati

MRTX NASDAQ
76.35
+1.86
+2.50%
Opening 14:06 05/24 EDT
Open
75.10
Prev Close
74.49
High
77.33
Low
75.10
Volume
205.33K
Avg Vol (3M)
642.30K
52 Week High
80.00
52 Week Low
28.50
% Turnover
0.57%
Market Cap
2.75B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).
MORE >

Recently

Name
Price
%Change